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Synopsis:
This systematic review of population-based studies evaluates the 30-day morbidity and mortality rates in patients
undergoing potentially curative surgical resection of primary retroperitoneal sarcoma (RPS). It also examined
predictors of overall survival. Morbidity and mortality rates in these patients were 23% and 3% respectively.
Five-year survival rates ranged from 52-62%. Recurrence rates were not widely reported.
2Abstract:
Retroperitoneal sarcomas (RPS) are rare mesenchymal tumours. Their rarity challenges our ability to understand
expected outcomes. The aim of this systematic review was to examine 30-day morbidity and mortality, overall
survival rates and prognostic predictors from population-based studies for patients undergoing curative resection
for primary RPS. A systematic literature review of EMBASE, MEDLINE, PUBMED and the Cochrane library
was performed using PRISMA for population-based studies reporting from nationally registered databases on
primary RPS surgical resections in adults. The main outcomes evaluated were 30-day morbidity and mortality
and overall survival rates. The use of additional treatment modalities and predictors of overall survival were also
examined. Fourteen studies (n=12 834 patients) reporting from 3 national databases, (Surveillance, Epidemiology
and End Results (SEER), the United States National Cancer Database (US NCDB) and the American College of
Surgeons’ National Surgical Quality Improvement Program (ACS NSQIP)) were analysed. The reported overall
30-day morbidity and mortality were 23% (n=191/846) and 3% (n=278/10 181) respectively. Reported use of
perioperative radiotherapy was 28%. No study reported loco-regional recurrence rates. Overall reported 5-year
survival ranged from 52% to 62%. Independent predictors of overall survival were age of the patient, resection
margin, tumour grade and size, histological subtype and receipt of radiotherapy. This review of population-based
data demonstrated relatively low 30-day morbidity rates in patients undergoing curative surgical resections for
primary RPS. Thirty-day mortality rates were similar to other abdominal tumour groups. There remains a paucity
of data reporting recurrence rates, however 5-year survival rates ranged from 52-62%.
KEYWORDS: 30-day morbidity and mortality, overall survival, predictors for overall survival, retroperitoneal
sarcomas, population-based studies
3INTRODUCTION:
Retroperitoneal sarcomas (RPS) are a rare heterogeneous group of mesenchymal tumours, representing
approximately 15% of soft tissue sarcomas[1, 2]. Their relatively late presentation and anatomical location
presents a therapeutic challenge. The often close relationship to vital structures in the retroperitoneum can impact
on the ability to perform a radical wide resection of the tumour and therefore it may not be possible to obtain a
margin of normal tissue around the tumour[3]. Marginal and incomplete resections (R1 or R2) have been reported
in up to half of patients undergoing surgery with curative intent[4-9]. Local recurrence is the main cause of
treatment failure, ranging from 40-80% and approximately 75% of sarcoma-related deaths involve uncontrolled
local recurrence[4]. Furthermore, in completely resected RPS, locoregional recurrence is common, occurring in
up of 50% of cases[10, 11].
Surgical resection currently represents the only possibility for cure, particularly due to the lack of effective
systemic treatments, and remains the mainstay of treatment for patients with RPS when it is deemed feasible.
There is great interest in strategies that might improve local control, such as radical surgical resection and peri-
operative radiotherapy, particularly because this represents the main cause of death after surgery. A radical
surgical approach involving en-bloc resection of the tumour with adherent organs or structures has been advocated
by many specialist centres with the aim to reduce margin involvement and decrease local recurrence rates[12-15].
Although improved oncological outcomes have been reported, the most common histological subtype of RPS is
liposarcoma, which can follow a relatively indolent course and display favourable tumour biology, therefore it
has been argued the potential short and long-term morbidity of aggressive multi-visceral resection is not always
justifiable[16, 17]. Despite the controversy surrounding the optimal surgical management of RPS, limited data
exists on the short-term peri-operative outcomes following resection of RPS. Peri-operative radiotherapy is the
most widely utilised multimodality strategy directed at decreasing locoregional recurrence in RPS, but at present,
data supporting the use is also limited and the increasing use of radiotherapy has largely been extrapolated from
its established role for soft tissue extremity sarcomas[18, 19].
The majority of data available on primary RPS surgical resection is from single specialist institutions or small
collaborative centres reporting outcomes for RPS. Furthermore, variations in practice regarding reporting of
resection margins, histology and post-operative surveillance can make it difficult to compare outcomes.
Consequently, findings from these studies have inherent biases and therefore may not be generalisable to a broader
population. Recently, there have been a growing number of population-based studies of RPS trying to address
4these issues. We therefore sort to systematically review these studies to examine the 30-day morbidity and
mortality, overall survival rates and predictors of this from population-based studies utilising large national
databases for patients undergoing curative resection for primary RPS.
METHODS:
Search strategy
A systematic review of published work was conducted as per the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA)[20] statement for the conduct of a review study. The study team
developed a concept table and built a search strategy with a medical librarian to identify articles reporting
outcomes from primary retroperitoneal sarcoma surgery. Three concepts were developed: retroperitoneal sarcoma,
post-operative morbidity and mortality (30-days) and surgery. Exploded medical subject heading (MeSH) terms
were combined with text word searching using the Boolean operator ‘OR’ for each concept. Each concept was
combined with ‘AND’. Variation in spelling were accounted for using ‘*’ in the search to represent wildcard
characters. Search limits were confined to the English language. Four databases were searched (Ovid Medline,
1946 to present; Ovid EMBASE, 1980 to present; PubMed and Cochrane database) and the search strategy was
adapted to each database. The final search was performed on 8th November 2017. Reference lists of included
articles were also searched and further articles included if appropriate. The full search strategy used is summarised
in Appendix 1.
Inclusion and exclusion criteria
To minimise selection, reporting and publication bias, any case reports or series and cohorts from single or
combined centres were excluded. Only population-based studies using nationally recognised central databases
were included.  The criteria were also refined to human adults (≥18 years) only.  The anatomical region for 
included tumours was defined as being inclusive of the retroperitoneal and abdominopelvic space. Reports that
did not focus on surgical resection as the main treatment option, and without curative intent were also omitted.
Any articles focusing on benign or recurrent disease, or those not originating from soft tissues were excluded.
Selection of articles
Using pre-defined data fields, two authors independently assessed the study titles and abstracts for inclusion. They
discussed and resolved any differences in title selection between them, with a third assessor independently
reconciling any differences in abstract selection. Full-text versions of potentially eligible studies were retrieved,
5which were further assessed by two independent study authors against the inclusion/exclusion criteria and a
consensus was reached.
Data extraction & outcomes
One author extracted information from the studies using a standardised spreadsheet. Data extracted included
study year, study design and purpose, patient demographics, 30-day morbidity and mortality, type of surgical
resection, histological factors, additional treatment modalities including chemotherapy and radiotherapy, overall
survival data and predictors of survival. The specific International Classification of Diseases (ICD) codes used
were also recorded.
Assessment of risk of bias in included studies
Two study authors assessed risk of bias independently and a third author resolved any discrepancies. The Quality
Assessment Tool for observational cohort or cross-sectional studies, developed by the National Heart, Lung, and
Blood Institute[21]. Data recorded included incomplete outcome data, clearly defined outcome measures and
other sources of bias. Studies were assigned good, fair or poor quality (low, moderate, high risk of bias) using
the published criteria and is outlined in Table 1.
Data synthesis
The heterogeneous nature of the methodology and data collected from this systematic review did not allow meta-
analysis to be conducted. When publications referred to the same population database and reported the same
outcome, the largest study was described.
Description of national databases
The Surveillance, Epidemiology and End Results (SEER) database is published by the National Cancer Institute
and is a coordinated system of cancer registries strategically located across the US[22]. The database covers
28% of the US population and draws data from 20 states[22]. One of the aims of the database is to evaluate the
quality of cancer care.
The US National Cancer Data Base (US NCDB) is a nationwide clinical oncology database, which is jointly
administered by the American College of Surgeons and the American Cancer Society. The US NCDB currently
includes records for more than 30 million patients and contains data from over 1 500 Commission on Cancer-
associated institutions in the USA[23]. The Commission on Cancer estimates the US NCDB captures
approximately 70% of newly diagnosed cancer cases in the USA[23].
6The American College of Surgeons National Surgical Improvement Program (ACS NSQIP) is a national initiative
that began in 2004 to collect validated, risk-adjusted 30-day perioperative outcome data from a variety of hospital
facilities[24]. This national database evaluates the quality of care at institutions and improves surgical
outcomes[24].
RESULTS:
Search results
One thousand and seventeen studies were identified from the literature search of the electronic databases, which,
following screening (inclusion/exclusion criteria and removal of duplicates), resulted in 14 full articles for
inclusion in this qualitative synthesis (Figure 1). All studies were assessed using the Quality Assessment Tool for
observational cohort or cross-sectional studies (Table 1).
Demographics of included studies
Of the 14 included studies reporting on 3 nationally recognised central databases, one was from Canada and the
USA25 and the others were all from the USA[26-38] (Table 1). Six studies used The Surveillance, Epidemiology
and End Results (SEER) database[25-30], five studies reported from the United States National Cancer Data Base
(US NCDB)[31-35] and the final three used the American College of Surgeons’ National Surgical Quality
Improvement Program (ACS NSQIP)[36-38]. The 14 studies span over four decades of surgical treatment for
retroperitoneal sarcomas, with the earliest studies reporting data from 1973[25, 28] and the most recent from
2015[31]. Overlapping of data in studies occurred across all the specific databases, therefore the largest dataset
was used for that particular database, unless the study did not report a specific outcome, when the next largest
sample study to report a specific outcome was used. The number of patients varied across the studies, but it
equated to a total of 12 834 patients from the largest series from each database[29, 33, 38]. Table 1 outlines the
characteristics of the 14 studies included, published between 2006 and 2017, which were all conducted as
retrospective data analyses. Table 2 summarises the aim of each study, the main reported outcomes pertinent to
this review and the basic reported demographic data, which varied depending on the database analysed. The
inclusion and exclusion criteria for each study is outlined in the Appendix 2.
7Frequency and type of surgical resection
The overall frequency of reported radical resections for RPS was 40% (4 528/11 449)[27, 33, 38]. Giuliano et al
reported 2208 patients from a total of 2 920 (76%) underwent surgical resection for primary RPS, but did not
specify the type of resection[29]. Tseng et al utilised the SEER database and specified the type of surgical
resection performed. From 1 535 patients, 660 (43%) underwent a complete resection (total removal or radical
surgery), 223 (15%) had incomplete resection (biopsy, debulking and destruction), 600 (39%) had simple
resection (excision or simple resection) and finally 52 (3%) were unknown[27].
Nussbaum et al reported on neo-adjuvant or adjuvant radiotherapy versus surgery alone for RPS in 9068 patients
from the US NCDB. Following imputation for missing variables and exclusion of neo-adjuvant radiotherapy
patients, as this data (not known at the time of pre-operative radiation) was not recorded (563 patients), 3 501
(41%) underwent radical resection (concomitant resection of neighbouring organ), 2 398 (28%) had simple
resection and 2 606 (31%) had local excision (includes excisional biopsy)[33]. Between 2004 and 2013, Ecker
et al reported on the use of neo-adjuvant radiotherapy in the management of retroperitoneal liposarcoma versus
surgery alone from data acquired from the US NCDB[32]. This study identified a total of 8 975 patients with RPS
in the US NCDB for this time period, which revealed 3 587 (40%) patients did not have surgery[32].
Park et al reported 846 patients that underwent surgical resection for a primary RPS from the ACS NSQIP
database[38]. A multi-visceral resection (concomitant adjacent organ resection) was reported in 367 (43%)
patients, but did not specify the type of organ resected. Bartlett et al reported on the early outcomes of 696 patients
from the use of neo-adjuvant therapy versus surgery alone for RPS from the ACS NSQIP between 2005 and 2011
and specified the type of organ resected. A major organ resection was performed in 371 (53%) patients, with 161
colonic (23%) and 134 kidney (19%) resections being the commonest organs removed[37].
30-day morbidity & mortality
Park et al is the largest study of 846 patients from the ACS NSQIP database to report these outcomes. The overall
(any ACS NSQIP complication) and serious (defined as Clavien-Dindo ≥3) reported 30-day morbidity were 23% 
(n=191/846) and 13% (109/846) respectively[38]. Univariate analysis demonstrated 30-day serious morbidity
were greater among males (18% versus 8%; p<0.0001), those that underwent multi-visceral resections (18%
versus 9%; p=0.0001), higher wound classification scores (p=0.01) and those with lower preoperative albumin
scores (p=0.04). Rates of serious 30-day morbidity were not significantly different among patients who underwent
neo-adjuvant chemotherapy (8% versus 13%; p=0.46) or radiotherapy (9% versus 13%; p=0.56), this was also the
8case for overall 30-day morbidity[38]. Significant predictors of 30-day serious morbidity on multivariate analysis
were multi-visceral resection (OR 1.86; 95% CI 1.19-2.89; p=0.006) and a modified frailty index (mFI: contains
11 variables) ≥3 compared with non-frail patients (OR 2.93; 95% CI 1.22-7.03; p=0.02)[38]. 
Studies from the SEER and US NCDB databases did not report 30-day morbidity rates[25-35]. However, Ecker
et al did report a hospital readmission rate within 30-days of 6.9% for the neo-adjuvant radiotherapy group (12/174
patients) and 6.3% for the surgery alone group (120/1 908 patients), with no statistical difference[32]. Bartlett et
al (n=696 patients) described a median length of hospital stay for primary RPS surgery of 7 days (range 1-78
days)[37].
Nussbaum et al[33] excluded 267 patients from their study because they died within 30-days of surgery (exclusion
criteria), whilst there were 11 (1%) deaths within 30-days of surgery in Park et al series (n=846 patients)[38].
Therefore, the overall reported 30-day mortality rate for primary RPS surgery was 3% (278/10 181 patients)[33,
38]. Univariate analysis of the Park et al series demonstrated increase rates of 30-day mortality among males
(2.2% versus 0.2%; p=0.0009), patients with impaired functional status (18% versus 1%; p<0.0001) and lower
mean haematocrit and albumin levels (p<0.01)[38]. Significant predictors of mortality on multivariate analysis
were male gender (OR 0.11; 95% CI 0.01-0.93; p=0.04) and impaired functional status (OR 44.17; 95% CI 5.65-
345.20; p<0.0001)[38]. Studies from the SEER database did not report 30-day mortality rates[25-30].
Histological factors
The proportion of histological subtypes are outlined in Table 2, demonstrating a wide variety of subtypes. The
important reported histological factors in the management of primary RPS are outlined in Table 3. This shows a
general trend towards the majority of tumours being >10cm in size and of a higher grade. Metastatic disease was
present in 15% of patients (2424/16 379)[29, 35], but the majority were excluded from individual studies.
Resection margins
Positive resection margins were reported in the adjuvant radiotherapy (n=2 215) and surgery alone (n=6 290)
groups in 874 (40%) and 1 851 (29%) patients respectively[33] from the US NCDB. Klooster et al evaluated the
long-term survival of patients after margin-positive resections of RPS using the US NCDB and demonstrated a
R2 resection rate of 3% (395/12 028 patients) between 1998 and 2011[34]. The reported R2 resection rate was
5% in 1998 versus 2.5% in 2011[34]. R2 resection margins were more likely to be associated with higher grade
(OR 1.80: 95% CI 1.10-3.20; p=0.03), tumour size ≥20cm (OR 2.10; 95% CI 1.10-4.20; p=0.03) and a 
9Charlson/Deyo score of 2 (OR 3.5; 95% CI 1.60-7.50; p=0.001). Neither the SEER nor the ACS NSQIP databases
report resection margins.
Additional treatment modalities
Radiotherapy:
A total of 3 598 patients (28%) across the largest studies from each of the 3 databases (n=12 834) received some
form of radiation therapy as part of their treatment for primary RPS[29, 33, 38]. A detailed breakdown of the
frequency of neo-adjuvant, intra-operative and adjuvant radiotherapy reported across these population studies is
outlined in Table 4.
Nussbaum et al report the use of neo-adjuvant or adjuvant radiotherapy versus surgery alone for RPS[33]. Factors
associated with the use of radiotherapy were estimated in logistic regression models. Variables associated with
the use of neo-adjuvant radiotherapy included age, sex, year of diagnosis, histological subtype, tumour grade and
treatment facility type. Variables associated with adjuvant radiotherapy were age, tumour size, histological
subtype, tumour grade, extent of resection, margin status and treatment facility type. Notably, treatment at
academic medical centres versus treatment at local community hospitals was associated with increased use of
neo-adjuvant radiotherapy (OR 7.98: 95% CI 3.53-18.06; p<0.0001) and decreased use of adjuvant radiotherapy
(OR 0.58: 95% CI 0.48-0.71; p<0.0001). Furthermore, use of neo-adjuvant radiotherapy was more frequent in
2007-2011 than in 2003-2006 (OR 1.40; 95% CI 1.19-1.74; p=0.0002), whilst the use of adjuvant radiotherapy
was unrelated to treatment period[33].
Chemotherapy:
Studies from the US NCDB and ACS NSQIP databases reported 606 (12%) from a total of 5 256 patients received
a form of chemotherapy[34, 35, 38]. A summary of the use of chemotherapy in primary RPS is provided in Table
5. Data for chemotherapy use is not available from the SEER database.
Local recurrence
No studies across the three population-based databases reported loco-regional recurrence rates[25-38].
Overall survival
Reported overall survival rates for primary RPS ranged between 52% and 62%. Giuliano et al reported overall
survival rates in 2 920 patients diagnosed with primary RPS that had varying treatment modalities (no treatment,
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surgery alone, radiotherapy alone and surgery & radiotherapy). The overall 5-year and 10-year survival rates in
this study were 58% and 45% respectively[29].
Propensity scores were calculated for the use of neo-adjuvant and adjuvant radiotherapy and were independently
matched to the surgery alone group in the Nussbaum et al study. The 1:2 matching for neo-adjuvant radiotherapy
versus surgery alone resulted in 1 126 matched pairs and a sample size of 1689 patients, whilst the 1:1 matching
for adjuvant radiotherapy versus surgery alone resulted in 2 196 matched pairs and a sample size of 4 392 patients.
In the matched neo-adjuvant radiotherapy group versus surgery alone survival analysis, the median follow-up
time was 42 months (IQR 27-70) and 43 months (IQR 25-64) respectively. The median overall survival was 110
months for the neo-adjuvant group versus 66 months in the surgery alone group (p<0.0001). The 5-year overall
survival rate was 62% in the neo-adjuvant radiotherapy group versus 54% in the surgery alone group (HR 0.70;
95% CI 0.59-0.82; p<0.0001). In the propensity matched adjuvant radiotherapy group versus surgery alone, the
median follow-up time was 54 months (IQR 32-79) and 47 months (IQR 26-72) respectively. Median overall
survival was 89 months for patients in the adjuvant radiotherapy group versus 64 months in the surgery alone
group (p<0.0001). The 5-year overall survival rate was 60% for the adjuvant radiotherapy group and 52% for the
surgery alone group (HR 0.78; 95% CI 0.71-0.85; p<0.0001)[33].
Overall 5-year survival rates for R2 resections were 24% (n=64; based on 272 cases with available survival data)
and the median overall survival for RPS with R2 resections was 21 months[34].
Studies from the ACS NSQIP do not report overall survival rates[36-38].
Predictors of overall survival
Ten out of the 14 studies reported predictors of overall survival. No study based on the ACS NSQIP database
report predictors of overall survival[36-38] as this is a database based on validated risk-adjusted 30-day peri-
operative outcome data.
On multi-variate survival analysis, Giuliano et al (n=2 920) showed increasing age, histological subtype,
increasing tumour grade and size, local advancement of the tumour, lymph node positivity and presence of distant
metastasis were associated with shorter survival time (Table 6). Operative resection was also an independent
predictor of survival versus no surgery and radiation therapy was a positive predictor for survival against no
radiation therapy. A combination of surgery and radiation therapy were also a positive predictor of survival versus
surgery alone (TR 1.31; 95%CI 1.06-1.61; p=0.011)[29].
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A secondary outcome of Nussbaum et al study (n=9 086) were factors associated with overall survival, which
were calculated using proportional hazards models in unmatched datasets, following imputation for missing
variables. The use of neo-adjuvant (HR 0.67: 95% CI 0.57-0.78; p<0.0001) and adjuvant radiotherapy (HR 0.77;
95% CI 0.71-0.83; p<0.0001) were independently associated with improved overall survival compared with
surgery alone. Other independent predictors of overall survival were age, sex, Charlson/Deyo comorbidity score,
income status, insurance status, tumour size, histological subtype and tumour grade. Extent of the surgical
resection and surgical margin status were also independent predictors of overall survival (Table 6). Notably,
adjuvant radiotherapy effect was not dependent on surgical margin status for overall survival (HR 0.93: 95%CI
0.79-1.10; p=0.38).
Predictors of overall survival for RPS with R2 resections were age ≥65, histological subtype and grade of 
tumour[34]. Regarding overall survival in RPS with R2 resections, only poorly differentiated grade was an
independent predictor of survival (HR 2.43; 95% CI 1.54-3.85; p<0.01)[34].
DISCUSSION:
This systematic review identified 14 population-based studies reporting outcomes from primary RPS surgical
resection. This population-based data demonstrated relatively low overall 30-day morbidity and mortality of 23%
(191/846 patients) and 3% (278/10 181 patients) respectively in patients undergoing surgical resection for
primary RPS. The reported use of peri-operative radiotherapy was variable across the studies at 28%, reflecting
the inconsistent and equivocal evidence that exists currently for systemic therapy in the management of RPS. No
study reported loco-regional recurrence rates, which is a reflection of the population-based databases evaluated
for outcomes for primary RPS surgical resections. Overall reported 5-year survival ranged from 52% to 62%.
Independent predictors of overall survival were age of the patient, comorbidity status, resection margin, tumour
grade and size, histological subtype and receipt of radiotherapy. These predictors for overall survival are similar
to other smaller studies[3, 39].
There are several limitations to this study, which need to be considered. Firstly, the study is retrospective, albeit
based on data collected from prospectively maintained databases. Interpretation of these results are limited by
heterogeneity, both within and between the included studies, which prevented a meta-analysis being conducted.
The majority of studies reflect the large heterogeneity of the condition, featuring numerous histological subtypes,
gradings and resection margins, whilst a small number focussed on smaller but more homogenous patient cohorts.
There were also large variations in treatment strategies reported across the studies, partly reflected by the paucity
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of therapeutic guidelines[40] and the differing treatment centres performing these cases. Variations in definitions
also existed between databases, for example surgical resection type of excision versus radical resection, so it is
difficult to objectively ascertain the true extent of the resection. There are also variations in the data collected
between databases, because they have different objectives, so not all variables are available from each data set,
for example the reported use of chemotherapy. However, in the absence of randomised controlled studies, this
systematic review of population-based studies provides large qualitative estimates of the clinical outcomes for the
management of primary RPS.
The serious morbidity rate of 13 % (109/846) described by Park et al[38] is comparable to the 16.4% from the
Trans-Atlantic RPS working group, which is an international collaborative of 8 specialist sarcoma centres
detailing the combined experience of 1007 patients[41]. However, 87% (876/1 007) of patients underwent en-
bloc resection of one or more organs41 in this series compared with 43% (367/846) in the Park et al study[38].
The 30-day mortality rate reported in this review of 3% is also comparable with other recent large studies, but
these focussed predominately on multi-visceral resections[3, 13, 41, 42] as already outlined. Maurice et al
recently evaluated the US NCDB for non-metastatic RPS cases to investigate the volume-outcome relationship in
RPS surgery[43]. From the 3 141 cases identified, hospital volume was an independent predictor for receiving
surgical management (OR 1.91; CI 1.37-2.68; p<0.001), a R0/R1 versus R2 resection (OR 2.47; CI 1.12-5.47;
p=0.026) and a R0 versus R1 resection (OR1.79; CI 1.30-2.46; p<0.001). High-volume centres were significantly
associated with improved surgical outcomes and suggests further centralisation of RPS care[43]. Centralisation
of services to reference centres for RPS surgery may eradicate or reduce some of the variabilities in treatment
strategies highlighted by this review, as the management requires specific expertise and is advocated by other
studies also[44-50].
Locoregional recurrence was not reported in any of the 14 included studies. The Trans-Atlantic RPS Working
Group are the largest series to report recurrent RPS, with 408 patients (41%) developing local recurrence, distant
metastasis or both from an initial 1 007 consecutive patients with primary RPS[51]. The median follow-up after
surgery from the primary tumour to local recurrence, distant metastasis or both were 76 (range 49-107), 59 (41-
89) and 70 (59-104) months respectively. The 5-year overall survival for local recurrence, distant metastasis or
both were 29%, 20% and 14% respectively. Predictors of overall survival after local recurrence were the time
interval to local recurrence and resection of local recurrence, whilst predictors for distant metastasis were time
interval and histological subtype[51]. Local control might also be optimised further by the use of pre-operative
radiotherapy[51]. The Trans-Atlantic Retroperitoneal Sarcoma Working Group aims to develop consensus
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treatment standards based on the strength of available evidence. With the paucity of supporting data, the 2015
consensus approach established that post-operative radiotherapy is of “no study-proven value” and that pre-
operative radiotherapy should only “be considered after careful review by a multi-disciplinary sarcoma tumour
board”40. However, there is growing evidence from more recent non-randomised observational studies, included
in this review, supporting the use of perioperative radiotherapy[32, 33] and a recent meta-analysis[53]. This
hypothesis is being evaluated in Europe with an ongoing multicentre randomised controlled trial assessing pre-
operative radiotherapy versus resection alone for primary RPS (EORTC 62092-22092; NCT01344018), but has
not completed recruiting at present[54]. The use of pre-operative radiotherapy is advantageous because the
tumour provides a defined target area and avoid unnecessary irradiation of normal tissue and may also improve
surgical margin negative resection[6, 55].
This review highlights the importance of an individualised discussion and treatment plan for patients with primary
RPS. The morbidity and mortality associated with surgical resection remains significant, which increases with
the complexity of resection, with multi-visceral resection being an independent predictor of morbidity and this
also has been demonstrated by an association of weighted organ score and severe adverse events in other
studies[13, 41].  Elderly patients, male sex and a Charlson/Deyo comorbidity score ≥2 are also associated with 
poorer outcomes and patients must be counselled accordingly when considering surgical intervention.
Furthermore, thoughtful consideration of the relative risks involved in achieving local control in the context of
overall tumour extent and anticipated disease biology is required[40], particularly as resection margin, tumour
grade and histological subtype are independent predictors for overall survival. The choice of treatment strategies
should be tailored to the specific histology[44]. Finally, there is limited evidence regarding long-term functional
outcomes following primary RPS resections, with sparse quality of life data[55], which should also be highlighted
when counselling patients regarding treatment options.
To our knowledge, this systematic review is the first attempt to pool the data from nationally registered databases
on this rare, but important condition, to assess surgical outcomes, use of systemic therapies, overall survival and
predictors of survival. The majority of previous studies are single-centre or small collaborative data, which have
their own inherent biases. This study provides an important and necessary summary of the current data, enabling
clinicians to better inform patients of the potential short and long-term outcomes in the management of primary
RPS.
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Figure Legend:
Figure 1: PRISMA flow diagram
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Table 1: Study demographics
Reference
(Author &
Year of
Publication)
Region Database Study
Period
Number of
Patients
Primary Aim of
Study
Risk of Bias
Porter et al
2006
North
America
SEER 1973-
2001
29 years
2 348
1 654
resections
Incidence,
treatment & use of
RT
Moderate
Nathan et al
2009
United
States of
America
SEER 1988 –
2005
27 years
1 365 Predictors of OS Good
Tseng et al
2011
United
States of
America
SEER 1988 –
2004
26 years
1 535 Effect of RT on OS Good/moderate
Bates et al
2015
United
States of
America
SEER 1973 -
2010
37 years
480 Efficacy of
Adjuvant RT in
high-grade RPS
Good/moderate
Giuliano et
al
2016
United
States of
America
SEER 2002 -
2012
10 years
2 920 Predictors of
improved OS
Moderate/poor
Wang et al
2017
United
States of
America
SEER 1988 –
2013
25 years
908 IntraopRT v
PreRT/PostRT
alone & OS
Moderate/poor
Kashtan et al
2016
United
States of
America
US NCDB 1998 –
2015
17 years
100 Age disparity in
treatment &
outcomes (OS) in
rhabdomyosarcoma
Moderate/poor
Ecker et al
2016
United
States of
America
US NCDB 2004 –
2013
9 years
2 082 PreRT v Surgery
alone & OS in
liposarcoma
Good
Nussbaum et
al 2016
United
States of
America
US NCDB 2003 –
2011
8 years
9 068 PreRT v PostRT v
Surgery alone &
OS
Good
Klooster et al
2016
United
States of
America
US NCDB 1998 –
2011
13 years
395 OS in R2 margin
status & predictors
Moderate
Stahl et al
2017
United
States of
America
US NCDB 1998 –
2011
13 years
4 015 R0 v R1 margin
status & OS
Good
Tseng et al
2011
United
States of
America
ACS-
NSQIP
2005 –
2007
2 years
156 30-day Morbidity
& Mortality,
predictors of poor
perioperative
outcome
Moderate
Bartlett et al
2014
United
States of
America
ACS-
NSQIP
2005 –
2011
6 years
696 30-day Morbidity
& Mortality PreRT
v no PreRT
Good/moderate
Park et al
2017
United
States of
America
ACS-
NSQIP
2007 –
2012
5 years
846 mFI as predictor of
30-day Morbidity
& Mortality
Good
RT: radiotherapy. PreRT: pre-operative radiotherapy. IntraopRT: intra-operative radiotherapy. PostRT: post-
operative radiotherapy. OS: overall survival. SEER: Surveillance, Epidemiology & End Results. US NCDB:
20
United States National Cancer Database. ACS-NSQIP: American College of Surgeons National Surgical
Improvement Program.
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Table 2: Main reported outcomes, basic patient demographic data and histology subtypes.
Reference (Author &
Year of Publication)
Main reported outcomes
pertinent to review
Patient Demographics Histology Types
SEER Subgroup
Porter et al
2006
Patient demographics
Treatment modalities
Use of RT
Geographical factors
N=2348
Male 1121 (48%)
Age<60 932 (40%)
Caucasian 1977 (84%)
All types of RPS
Histological subtypes not
specified
Nathan et al
2009
Patient demographics
Histological Factors
Lymph Node &
Metastatic disease
Use of RT
AJCC staging
Overall survival
Predictors of overall
survival
N=2500
Curative surgery = 1365
(55%)
N=1365
Female 754 (55%)
Median Age 63
Caucasian 1135 (83%)
All types of RPS
Liposarcoma (50%)
Leiomyosarcoma (26%)
Malignant fibrous
histiocytoma (11%)
Fibrosarcoma (2%)
Rhabdomyosarcoma
(1%)
Malignant peripheral
nerve sheath tumour
(1%)
Sarcoma not specified
(7%)
Others (2%)
Tseng et al
2011
Patient demographics
Histological Factors
Perioperative variables
Use of RT
RT v surgery alone
Overall and disease
specific survival
Predictors of overall and
disease-specific survival
N=1535
Male 723 (47%)
Mean Age 61.5 (14.8
SD)
Caucasian 1157 (75%)
All types of RPS
Liposarcoma (49%)
Leiomyosarcoma (28%)
Malignant fibrous
histiocytoma (10%)
Sarcoma not specified
(7%)
Others (6%)
Bates et al
2015
Patient demographics
Use of RT
Surgery & PostRT v
Surgery alone
Overall survival
Predictors of overall
survival
N=480
Male 241 (50%)
Age≤65 279 (58%) 
Caucasian 404 (84%)
All types of high grade
RPS
Leiomyosarcoma (29%)
Dedifferentitated
Liposarcoma (28%)
Malignant fibrous
histiocytoma (10%)
Sarcoma not specified
(%)
Giuliano et al
2016
Patient demographics
Histological factors
Lymph node &
Metastatic disease
Treatment modalities
Use of RT
Overall and cause-
specific mortality
Predictors of overall
survival
N=2920
Female 1506 (51.6%)
Median Age 63 (52-73
IQR)
Caucasian 2360 (81%)
All types of RPS
Liposarcoma (47%)
Leiomyosarcoma (25%)
Sarcoma not specified
(14%)
Others (14%)
Wang et al
2017
Patient demographics
Histological factors
Use of RT
IntraopRT v
PreRT/PostRT alone
Overall survival
Predictors of overall
survival
N=908
Female 432 (48%)
Age≤65 608 (67%) 
Caucasian 715 (79%)
All types of RPS
Liposarcoma (42%)
Leiomyosarcoma (31%)
Rhabdomyosarcoma
(2%)
Fibrosarcoma (2%)
Malignant fibrous
histiocytoma (8%)
22
Sarcoma not specified
(15%)
US NCDB Subgroup
Kashtan et al
2016
Patient demographics
Histological factors
Institutional factors
Perioperative factors
Use of RT & Chemo
Age based disparity
Overall Survival
Predictors of overall
survival
N=100
Male 51
Age<65 65
Caucasian 79
Charlson Deyo Score 0
52
Private Insurance 50
Median income >
$46000 40
Rhabdomyosarcoma
(100%)
Ecker et al
2016
Patient demographics
Histological factors
Institutional factors
Use of Chemo
Pre-RT v Surgery alone
(Propensity score
matching)
Overall survival
Predictors of overall
survival
N=2082
Male 1092 (52%)
Age≤63 1000 (48%) 
Caucasian 1849 (89%)
Charlson Deyo Score 0
1631 (78%)
Private Insurance 939
(45%)
Median Income ≥$48000 
1350 (65%)
Liposarcoma (100%)
Nussbaum et al
2016
Patient Demographics
Histological factors
Institutional factors
30-day mortality
Pre-RT or Post-RT v
Surgery alone
(Propensity Score
Matching)
Overall Survival
Predictors of Overall
Survival
N=9068
Male 4390 (48%)
Mean Age 60
Caucasian 7713 (85%)
Charlson Deyo Score 0
7276 (80%)
Insurance 8568 (94%)
Above median income
5481 (60%)
All types of RPS
Liposarcoma (47%)
Leiomyosarcoma (30%)
Haemangiosarcoma (1%)
Malignant fibrous
histiocytoma (5%)
Malignant peripheral
nerve sheath tumour
(2%)
Fibrosarcoma (2%)
Spindle Cell sarcoma
(3%)
Giant cell sarcoma (4%)
Sarcoma not specified
(6%)
Klooster et al
2016
Patient demographics
Histological factors
Institutional factors
Use of RT & Chemo
R2 Resection Margin
Overall survival
Predictors of overall
survival
N=395
Male 173 (44%)
Age<65 218 (55%)
Charlson Deyo Score 0
180 (46%)
All types of RPS
Liposarcoma (41%)
Leiomyosarcoma (18%)
Undifferentiated
pleomorphic sarcoma
(19%)
Fibrosarcoma (1.5%)
Malignant peripheral
nerve sheath tumour
(1.5%)
Sarcoma not specified
(19%)
Stahl et al
2017
Patient Demographics
Histological Factors
Use of RT & Chemo
R0 v R1 Resection
Margins (Propensity
Score Matching)
Overall Survival
Predictors of Overall
Survival
N=4015
Female 2201 (55%)
Age <60 1920 (48%)
Caucasian 3348 (83%)
Charlson Deyo score 0
2293 (57%)
All types of RPS
Liposarcoma (59%)
Further histological
subtypes not specified
ACS-NSQIP Subgroup
Tseng et al Patient Demographics N=156 All types of RPS
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2011 Perioperative variables
Use of PreRT
30-day Overall
Morbidity
30-day Serious
Morbidity
30-day Mortality
Predictors of 30-day
overall & serious
morbidity
Female 82 (53%)
Mean Age 59.5 (+/-
15.2SD)
Caucasian 117 (75%)
ASA 1/2 78 (50%)
Mean BMI 29.8 (+/-
7.4SD)
Hypertension 65 (42%)
Smoker 20 (13%)
Diabetes Mellitus 19
(12%)
Histological subtypes not
specified
Bartlett et al
2014
Patient Demographics
Perioperative variables
Length of Hospital Stay
Use of PreRT
30-day Morbidity
30-day Mortality
Predictors of Morbidity
& Mortality
N=696
Male 342 (49%)
Median Age 60 (19-90)
Independent Functional
Status 678 (98%)
BMI>25 532 (77%)
Hypertension 304 (44%)
Smoker 78 (11%)
Diabetes 82 (12%)
All types of RPS
Histological subtypes not
specified
Park et al
2017
Patient Demographics
Perioperative Variables
30-day Overall
Morbidity
30-day Serious
Morbidity
30-day Mortality
Predictors of 30-day
overall morbidity,
serious morbidity &
mortality
N=846
Female 437 (52%)
Mean Age 59 (+/-14SD)
Caucasian 667 (79%)
Mean BMI 28.7 (+/-
2.6SD)
ASA 1/2 302 (36%)
Independent Functional
status 824 (97%)
mFI score 0 410 (49%)
All types of RPS
Histological subtypes not
specified
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Table 3: A summary of the reported histological factors. SD: standard deviation.
Reference Tumour
Grade
Tumour Size Local Extension Lymph
Nodes
Metastasis
SEER
Giuliano et al
2016
(n=2920)
Grade 1 719
(24%)
Grade 2 286
(10%)
Grade 3&4
1189 (41%)
Unknown
726 (25%)
<10cm 754 (26%)
≥10cm 1804 (62%) 
Unknown 362 (12%)
Confined to
primary 558
(19%)
Localised 640
(22%)
Adjacent
connective tissue
348 (12%)
Adjacent
organ/structure
1152 (40%)
Unknown 222
(7%)
Yes 133
(5%)
No 2396
(82%)
Unknown
391 (13%)
Yes 425 (15%)
No 2309 (79%)
Unknown 186
(6%)
Metastatic
patients:
191 (45%) no
treatment
147 (35%)
Surgery alone
37 (9%)
Surgery &
Radiotherapy
43 (10%)
Radiotherapy
only
7 (1%) Not
reported
US NCDB
Nussbaum et
al 2016
(n=9068)
Grade 1 3351
(37%)
Grade 2 1174
(13%)
Grade 3 4543
(50%)
No Radiotherapy
Group:
Mean 16cm (+/-12.5
SD)
Neo-adjuvant
Radiotherapy
Mean 15.4cm (+/-
11.9 SD)
Adjuvant
Radiotherapy Mean
12.7 cm (+/-11.5
SD)
Not reported
Ecker et al 2016
reported adjacent
organ invasion
independent
predictor of risk
of death HR1.50
(1.25-1.81
p<0.001)
Not reported Excluded from
study
Stahl et al 2017
reported 1999
patients (15%)
excluded due to
metastatic
disease from
total 13459
patients with
RPS in US
NCDB
ACS NSQIP
Park et al
2017
(n=846)
Not reported ≤5cm 158 (19%) 
5.1-10cm 129 (15%)
>10cm 442 (52%)
Unknown 117 (14%)
No association on
univariate analysis
with 30-day
morbidity/mortality
Not reported Not reported Not reported
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Table 4: The reported use of radiotherapy in the treatment of primary RPS.
IORT: Intra-operative radiotherapy. EBRT: External beam radiotherapy (peri-operative). Porter et al is
reported in this table because Giuliano et al did not report the specific timings of the radiotherapy.
Use of Radiotherapy
Study Neo-adjuvant
Radiotherapy
Intraoperative
Radiotherapy
Adjuvant
Radiotherapy
SEER
Giuliano et al 2016
(n=2920)
All Radiation therapy (timing not specified) 756 (26%)
Radiation therapy alone (no surgery) 125 (4%)
Porter et al 2006
(n=1654 patients
undergoing surgical
resection)
20 (1%) 22 (1%)
Wang et al 2016 (n=908
patients)
IORT alone 33 (4%)
IORT & EBRT 32 (4%)
366 (22%)
US NCDB
Nussbaum et al 2016
(n=9068)
563 (6%) Excluded from study
Stahl et al 2017
IORT 57/4015 (1%)
2215 (24%)
ACS NSQIP
Park et al 2017
(n=846)
64 (8%) Not recorded in any
study
Not recorded in any
study
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Table 5: The reported use of chemotherapy in the treatment of primary RPS.
Study Use of Chemotherapy
SEER
Giuliano et al 2016
(n=2920)
Not reported
No study reported Chemotherapy use (data unavailable in SEER)
US NCDB
Nussbaum et al 2016
(n=9068)
Not reported
Stahl et al 2017
(n=4015)
445 (11%) patients received chemotherapy in total
R0 resection (n=2593): 258 patients (10%) received chemotherapy
R1 resection (n=1422): 187 patients (14%) received chemotherapy
Klooster et al 2016
(n=395)
122 (31%) patients with R2 resection received chemotherapy
ACS NSQIP
Park et al 2017
(n=846)
39 patients (5%) received pre-operative chemotherapy
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Table 6: Predictors of overall survival in RPS.
Study
SEER
Predictors of Overall
Survival
Multi-variate Analysis
Time Ratio (95% CI)
Giuliano et al 2016
(n=2920)
Age
Grade 3 or 4
Tumour size ≥ 10cm 
Extension to adjacent
organs
Lymph node positive
Distant metastasis positive
Surgery
Radiation therapy
TR 0.98 (0.97-0.98) p<0.001
TR 0.26 (0.20-0.33) p<0.001
TR 0.59 (0.49-0.71) p<0.001
TR 0.56 (0.51-0.70) p<0.001
TR 0.64 (0.46-0.89) p=0.007
TR 0.43 (0.34-0.53) p<0.001
TR 2.45 (2.02-2.98) p<0.001
TR 1.34 (1.12-1.61) p=0.001
US NCDB
Predictors of Overall
Survival
Neo-adjuvant
radiotherapy versus
surgery alone
Hazard Ratios (95% CI)
Adjuvant radiotherapy
versus surgery alone
Hazard Ratios (95% CI)
Nussbaum et al 2016
(n=9068)
Age per 5 years
Male Sex
Charlson/Deyo
Comorbidity Score ≥2 
Income above median
Patient insured
Tumour size per 5cm
Grade 3
Simple surgical resection
R1 resection margin
1.15 (1.13-1.17) p<0.0001
1.11 (1.02-1.20) p=0.013
1.70 (1.44-2.02) p<0.0001
0.91 (0.84-0.98) p=0.015
0.76 (0.59-0.97) p=0.025
1.07 (1.05-1.08) p<0.0001
2.16 (1.92-2.44) p<0.0001
-
-
1.14 (1.12-1.15) p<0.0001
1.11 (1.03-1.19) p=0.0069
1.61 (1.38-1.88) p<0.0001
0.88 (0.82-0.95) p=0.0004
0.75 (0.61-0.92) p=0.0068
1.06 (1.05-1.07) p<0.0001
2.13 (1.86-2.43) p<0.0001
1.12 (1.03-1.22) p=0.011
1.51 (1.39-1.64) p<0.0001
ACS NSQIP
Park et al 2016
(n=846)
Predictors of overall survival not reported in this study
Data not available from ACS NSQIP database
